Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.85
Bid: 4.70
Ask: 5.00
Change: 0.00 (0.00%)
Spread: 0.30 (6.383%)
Open: 4.85
High: 4.85
Low: 4.85
Prev. Close: 4.85
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of AGM, investor conference & Accounts

7 Jun 2021 15:28

RNS Number : 0754B
Eden Research plc
07 June 2021
 

7 June 2021

 

Eden Research Plc

("Eden" or "Company")

 

Notice of AGM, virtual investor conference and 2020 Accounts

 

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, announces that its Notice of the Annual General Meeting ("AGM") has been issued to shareholders and is now available on the Company's website: www.edenresearch.com 

The AGM is to be held on Wednesday 30 June 2021 at 12.00pm at 67C Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RQ.

In accordance with current Government regulations in relation to COVID-19, shareholders are encouraged to submit their Form of Proxy in advance of the General Meeting and are strongly discouraged from attending the General Meeting in person to safeguard the Company's shareholders' and employees' health, to comply with current Government guidelines, to minimise the unnecessary movement of people and to make the AGM as safe and efficient as possible.

Should shareholders wish to ask any questions in relation to the Resolutions, which they may otherwise have asked at the AGM, had they been in attendance, they are encouraged to contact the Company prior to the AGM by email at agm@edenresearch.com.

Virtual Investor Conference

Given the advised restrictions in place for the AGM due to COVID-19, the Company shall be holding a virtual investor conference at 1pm on 30 June 2021, where the executive team at Eden shall make a presentation to shareholders and other interested parties and shall answer questions that have been submitted to the Board ahead of time. Should you have any questions for the Board, please send them by email to agm@edenresearch.com by 5pm on Friday 25 June 2021.

Details of how to join the virtual investor conference shall follow in due course.

 

2020 Accounts

 

In addition, and following discussions with the Company's auditors and regulatory guidance in relation to the ongoing COVID-19 pandemic, the Company has received an extension to the timeline for filing its 2020 Accounts at Companies House. Accordingly, the Company's consolidated accounts for the year ended 31 December 2020 (the "2020 Accounts") will not be presented at the AGM.

 

The Company continues to work with its auditors to finalise its 2020 Accounts and, when available, the Company will issue an RNS and dispatch the annual report and accounts to shareholders. At that stage the Company intends to call a further general meeting to receive the annual report and accounts.

 

 

 

For further information contact:

 

Eden Research plc

www.edenresearch.com

Sean SmithAlex Abrey

01285 359 555

 

Cenkos Securities plc (Nominated advisor and broker)

Giles Balleny / Camilla Hume/ Mark Connelly (corporate finance)Michael Johnson (sales)

020 7397 8900

 

Hawthorn Advisors (Financial PR)

Lorna Cobbett / Victoria Ainsworth

eden@hawthornadvisors.com

 

 

 

 

 

 

Notes to Editors:

 

Eden Research is an AIM quoted company that develops and supplies breakthrough biopesticide products and natural, plastic-free microencapsulation technologies to the global crop protection, animal health and consumer products industries.

 

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Eden has numerous patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. Eden was admitted to trading on AIM in May 2012.

 

For more information about Eden, please visit: www.edenresearch.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOASSWFLWEFSEEM
Date   Source Headline
15th Sep 20157:00 amRNSHalf Yearly Report
1st Sep 20157:03 amRNSProduct approval in Greece
24th Aug 20157:00 amRNSTerpeneTech Licence Agreement and Investment
25th Jun 20157:00 amRNSActive substances approved for MRL exemption
10th Jun 201512:25 pmRNSResult of AGM
10th Jun 20157:00 amRNSAGM Statement
27th May 20157:00 amRNSDirector/PDMR Shareholding
26th May 20157:01 amRNSEU Product Authorisation
20th May 201510:07 amRNSPosting of Annual Report & Notice of AGM
20th May 20157:00 amRNSAgreement with Sipcam covering new products
11th May 20157:00 amRNSAppointment of a Director and Share Options
13th Apr 20157:00 amRNSOption agreement with Taminco
30th Mar 20157:00 amRNSFinal Results
18th Feb 201511:08 amRNSDeath of a Director
2nd Feb 20157:00 amRNSGrant of Patent in South Korea
8th Jan 20157:00 amRNSDirectorate Change
19th Dec 20147:00 amRNSProgress on EU zone approval
1st Dec 20147:00 amRNSLicence Agreement with SUMIAGRO
28th Nov 20147:00 amRNSConversion of all outstanding debt
21st Nov 20143:26 pmRNSPlacing to raise £750,000
21st Nov 20147:00 amRNSLicence Agreement with SIPCAM
29th Sep 20147:00 amRNSSuccessful trials in Greece to combat Botrytis
29th Sep 20147:00 amRNSHalf Yearly Report
18th Aug 20147:00 amRNSDirectorate changes & share options
11th Aug 20147:00 amRNSEvaluation agreement for nematicide
1st Jul 20147:00 amRNSNotice of Decision of Patent in South Korea
26th Jun 201412:37 pmRNSAGM Statement
6th Jun 201410:46 amRNSPosting of Annual Report & Notice of AGM
6th Jun 20147:00 amRNSExtension of TerpeneTech licence agreement
30th May 20147:00 amRNSPreliminary Results
15th May 20147:00 amRNSNotice of Allowance for Mexican patent
8th May 20145:12 pmRNSDeath of a Director
24th Apr 20147:00 amRNSNotice of Allowance for Canada patent
22nd Apr 20147:01 amRNSFirst commercial products launched with Eden tech
10th Mar 20147:00 amRNSFurther progress in EU product approval
13th Jan 20147:00 amRNSData Access Licence and Royalty Agreement
19th Nov 201312:54 pmRNSHolding(s) in Company
18th Nov 201311:48 amRNSHolding(s) in Company
9th Oct 20137:00 amRNSNotice of Allowance from ARIPO
24th Sep 20137:00 amRNSHalf Yearly Report
28th Aug 20137:00 amRNSNotice of Allowance
27th Aug 201310:33 amRNSHolding(s) in Company
24th Jun 20131:39 pmRNSResult of AGM
24th Jun 20137:00 amRNSAGM Statement
5th Jun 20137:00 amRNSLicence agreement for head lice treatment
31st May 20135:22 pmRNSPosting of Annual Report & Notice of AGM
31st May 20137:08 amRNSPreliminary Results
20th May 20137:00 amRNSEU approval for active substances
25th Apr 20137:00 amRNSNotice of Allowance from ARIPO
16th Apr 201311:40 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.